DNA甲基化识别MDS基因与预后不同的亚型
基于非负矩阵分解识别出5个稳定的甲基化簇,各簇与特定遗传异常相关并独立关联总生存。靶向DNA甲基化谱可识别突变或临床特征未区分的MDS临床相关亚型。
要点
- DNA甲基化谱将MDS分为5个稳定亚型,各亚型与特定遗传异常相关
- 甲基化亚型在多变量分析中独立关联总生存
- 不同遗传损伤患者可汇聚于共同甲基化状态,共享致病机制与临床结局
核心结论
- 靶向DNA甲基化谱可识别突变或临床特征未区分的MDS临床相关亚型
- 不同遗传损伤患者可汇聚于共同甲基化状态,共享致病机制与临床结局
研究设计与样本
- 应用基于非负矩阵分解的DNA甲基化谱分解,识别出5个共识簇作为最稳定分组方案
主要发现
- 5个NMF组分各与特定遗传异常相关,将患者分为5个不同甲基化簇,每簇主要由单一NMF组分定义
- 甲基化簇显示独特差异甲基化调控位点,富集于活跃和二价启动子及增强子
- 两个簇富集复杂核型样本,但仅一个簇TP53突变增加
- 三个最常突变剪接因子SF3B1、U2AF1和SRSF2分别富集于不同簇
- ASXL1、EZH2和RUNX1突变在含SRSF2的簇中共富集;多变量分析中甲基化簇归属独立关联总生存
临床怎么用
- DNA甲基化分型可作为MDS预后分层与生物学理解的补充工具
- 对突变或临床特征无法区分的MDS患者,可考虑甲基化谱识别临床相关亚型
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Recurrent mutations implicate several epigenetic regulators in the early molecular pathobiology of myelodysplastic syndromes (MDS). We hypothesized that MDS subtypes defined by DNA methylation (DNAm) patterns could enhance our understanding of MDS disease biology and identify patients with convergent epigenetic profiles. Bisulfite padlock probe sequencing was used to measure DNAm of ∼500 000 unique cytosine guanine dinucleotides covering 140 749 nonoverlapping regulatory regions across the genome in bone marrow DNA samples from 141 patients with MDS. Application of a nonnegative matrix factorization (NMF)-based decomposition of DNAm profiles identified 5 consensus clusters described by 5 NMF components as the most stable grouping solution. Each of the 5 NMF components identified by this approach correlated with specific genetic abnormalities and categorized patients into 5 distinct methylation clusters, each largely defined by a single NMF component. Methylation clusters displayed unique differentially methylated regulatory loci enriched for active and bivalent promoters and enhancers. Two clusters were enriched for samples with complex karyotypes, although only one had an increased number of TP53 mutations. Each of the 3 most frequently mutated splicing factors, SF3B1, U2AF1, and SRSF2, was enriched in different clusters. Mutations of ASXL1, EZH2, and RUNX1 were coenriched in the SRSF2-containing cluster. In multivariate analysis, methylation cluster membership remained independently associated with overall survival. Targeted DNAm profiles identify clinically relevant subtypes of MDS not otherwise distinguished by mutations or clinical features. Patients with diverse genetic lesions can converge on common DNAm states with shared pathogenic mechanisms and clinical outcomes.
引用
- Reilly B, Tanaka TN, Diep D, et al. DNA methylation identifies genetically and prognostically distinct subtypes of myelodysplastic syndromes. Blood Adv. 2019. PMID: 31582393. doi:10.1182/bloodadvances.2019000192
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。